6 Critical Facts About Maryland's Landmark Price Cap on Ozempic

In a groundbreaking move that could reshape how states tackle soaring drug costs, Maryland's Prescription Drug Affordability Board (PDAB) has set a price ceiling on Ozempic, a widely used diabetes medication. This action, the second of its kind by the board in recent weeks, aims to control expenses for state and local governments. Here are six essential things you need to know about this development.

1. What Is the Maryland Prescription Drug Affordability Board?

The Maryland PDAB operates like a state utility commission—but for prescription drugs. Established to curb excessive pricing, it has the authority to set upper payment limits (UPLs) on costly medications. Think of it as a watchdog that steps in when drug prices spiral beyond reasonable benchmarks. The board's decisions affect what the state, local governments, and eventually all Marylanders pay for certain high-cost drugs. By functioning similarly to how utilities regulate electricity rates, the PDAB injects transparency and accountability into a market often opaque. This structure allows Maryland to act where federal efforts have stalled, making it a pioneering force in drug affordability.

2. Ozempic’s Price Cap: $274 for a 30-Day Supply

The board voted to cap Ozempic—a type 2 diabetes treatment from Novo Nordisk—at 274 USD per 30-day supply. This limit applies specifically to purchases by the state and local governments, not yet to commercial insurers. The cap represents a significant reduction from current market prices, which can exceed $900 per month without insurance. By setting this ceiling, Maryland ensures that its public sector health plans no longer bear the full brunt of manufacturer list prices. The move is precedent-setting: it's one of the first times a state has directly limited what it will pay for a specific brand-name drug, bypassing traditional rebate negotiations.

3. Why Was This Price Chosen?

The cap was benchmarked against the maximum fair price paid by Medicare, according to Andrew York, executive director of the Maryland PDAB. This reference point ensures the limit aligns with what the federal government already deems reasonable. Medicare’s pricing reflects negotiated rates under the Inflation Reduction Act, which caps certain drugs for beneficiaries. By using this metric, Maryland avoids arbitrary cuts and ties its policy to an existing, vetted standard. The board’s approach also considers cost-effectiveness and therapeutic value, aiming to balance affordability with access. Such benchmarking could serve as a model for other states looking to rein in drug spending without harming innovation.

4. Projected Savings: $5.8 Million Annually

Maryland estimates that the Ozempic price cap will save the state and local governments 5.8 million USD per year. These savings come directly from reducing what public health programs—like those covering state employees and retirees—pay for the drug. The board calculates that by lowering the per-month cost to $274, overall expenditures drop sharply. Importantly, this money can be redirected to other healthcare priorities, such as preventive services or lower premiums. Savings projections like these are crucial for building political and public support for PDAB actions, especially as the board prepares to extend caps to the broader commercial market.

5. Timeline: Implementation by January 2027

The board will oversee a process to implement the cap by January 2027. Until then, state and local government purchasers will continue paying current prices while the PDAB finalizes rules and contracts. After that date, any purchase above $274 for a 30-day Ozempic supply would violate the UPL, triggering enforcement mechanisms. Looking further ahead, by 2028, the board plans to set upper payment limits on high-cost drugs purchased by all Marylanders in the commercial insurance market. This phased approach allows stakeholders—manufacturers, insurers, pharmacies—to adapt slowly. It also gives the board time to refine its methodology based on early data from the Ozempic cap.

6. What This Means for Drug Pricing Reform Nationwide

Maryland’s action on Ozempic marks the second time the PDAB has used its authority—a sign that the board is gaining momentum. Other states, including Colorado and Washington, have established similar boards but are earlier in their implementation. Maryland’s choice to focus on a high-profile drug like Ozempic, which is also used off-label for weight loss, amplifies its impact. If successful, the cap could encourage more states to follow suit, creating a patchwork of UPLs that pressure manufacturers to lower list prices nationwide. However, legal challenges from the pharmaceutical industry are expected, arguing that state price controls interfere with interstate commerce. The outcome will be closely watched by policymakers, patient advocates, and drugmakers alike.

The Maryland PDAB’s decision to cap Ozempic is a bold experiment in state-level drug pricing regulation. With thousands of dollars in potential savings and a clear timeline, it sets a precedent for how governments can push back against unaffordable medicines. Whether this approach will survive legal tests and expand to all residents remains to be seen, but for now, it’s a crucial step toward making essential treatments accessible.